The complete science of delta-9-THC: chemical structure, receptor binding, THCA decarboxylation, isomers, medical applications and drug test detection.
Tetrahydrocannabinol, known universally as THC, is the primary psychoactive compound produced by the Cannabis sativa plant. Its full chemical name is (−)-trans-Δ9-tetrahydrocannabinol, with the molecular formula C21H30O2 and a molecular weight of 314.47 g/mol. THC belongs to a class of compounds called phytocannabinoids and is one of approximately 140 cannabinoids identified in cannabis to date.
THC was first isolated, characterised and synthesised by Israeli chemist Dr. Raphael Mechoulam and his colleague Dr. Yechiel Gaoni at the Weizmann Institute of Science in 1964. This landmark achievement established the structural basis for understanding cannabis pharmacology and ultimately led to the discovery of the endocannabinoid system decades later. Mechoulam’s work is considered one of the most significant contributions to pharmacology in the 20th century and earned him the informal title "father of cannabis research."
In the living cannabis plant, THC does not exist in its active delta-9 form. It is biosynthesised as THCA (tetrahydrocannabinolic acid), the carboxylated, non-intoxicating precursor. Only when THCA is exposed to heat or prolonged UV radiation does it undergo decarboxylation, converting to the active delta-9-THC. This is why raw cannabis does not cause intoxication when eaten, and why heating — through smoking, vaporising or cooking — is required to activate its psychoactive potential.
THC concentration in commercially available cannabis has risen dramatically over recent decades. Average THC in retail flower increased from approximately 4% in the early 1990s to over 12% by 2014 and is now routinely above 20–25% in top-shelf retail products. Concentrates push this further, regularly exceeding 70–90% total cannabinoids. This potency escalation has significant implications for tolerance development, adverse event rates and dosing guidance.
The three-dimensional structure of THC is key to understanding its pharmacological behaviour. THC has a tricyclic dibenzopyran ring system with an aliphatic side chain of five carbon atoms (pentyl chain) — this side chain length is critical for receptor binding affinity. The unique molecular geometry allows THC to fit into the orthosteric binding pocket of cannabinoid receptors.
THC is a partial agonist at CB1 receptors in the brain and central nervous system, and a weaker partial agonist at CB2 receptors found predominantly in immune tissues. The distinction between partial and full agonism matters: a partial agonist activates the receptor but produces a submaximal response even at saturating concentrations. This limits the ceiling effect of THC and is why cannabis does not cause respiratory depression even at high doses — unlike opioid full agonists at mu receptors, THC partial agonism at CB1 cannot suppress the brainstem breathing centres to lethal levels.
CB1 receptors are G-protein-coupled receptors (GPCRs) that couple primarily to Gi/o proteins. When THC binds and activates CB1, the receptor initiates a cascade: inhibition of adenylyl cyclase (reducing cAMP), activation of inwardly rectifying potassium channels (hyperpolarising the neuron), and inhibition of voltage-gated calcium channels (reducing neurotransmitter release). The net effect is reduced neuronal firing and suppressed synaptic transmission — producing THC’s characteristic effects: mood elevation, altered time perception, memory impairment, appetite stimulation and, at higher doses, sedation and euphoria.
The highest density of CB1 receptors is found in the basal ganglia (movement), hippocampus (memory), cerebral cortex (cognition), cerebellum (coordination) and limbic system (emotion). The near-absence of CB1 receptors in the brainstem nuclei controlling respiration explains why, unlike alcohol or opioids, there is no medically established lethal dose of THC through direct pharmacological mechanism.
CB2 receptor activation by THC contributes to its anti-inflammatory and immunomodulatory effects. CB2 receptors are expressed on macrophages, T-cells, B-cells and natural killer cells. THC’s partial agonism at CB2 suppresses pro-inflammatory cytokine production and may explain part of its observed benefit in autoimmune and inflammatory conditions.
In fresh, undried cannabis, nearly all cannabinoid content exists as carboxylic acids — THCA, CBDA, CBGA — not as the neutral active cannabinoids. These acidic forms carry a carboxyl group (-COOH) that prevents them from binding CB1 receptors with meaningful affinity, rendering them non-intoxicating in their raw state.
Decarboxylation removes the carboxyl group as CO2, converting THCA to delta-9-THC. This occurs spontaneously at room temperature over months as cannabis dries and ages, and rapidly when heat is applied. The thermal profile is well characterised: significant conversion begins around 80–100°C and reaches near-complete conversion at 104–115°C. Full decarboxylation at 115°C takes approximately 45–60 minutes; at higher temperatures conversion is faster but terpene degradation increases substantially.
For home edible preparation, this chemistry has critical practical implications. Raw cannabis added to cold butter produces a THCA-rich product with negligible psychoactivity. The same cannabis simmered in butter at 80–90°C for 30–45 minutes undergoes meaningful decarboxylation, creating active THC-infused fat. Many commercial edible producers pre-decarboxylate cannabis in a dedicated oven step before extraction to ensure complete, reproducible conversion.
Once THC is formed, it degrades further through oxidation — particularly under UV light exposure — to cannabinol (CBN), a mildly sedating cannabinoid with approximately 10% of THC’s potency. Well-cured cannabis stored in dark, airtight, temperature-stable conditions retains potency over months; improperly stored material oxidises and becomes CBN-dominant, explaining the more sedating character of old or poorly stored flower.
"THC" without qualification refers to delta-9-THC, but the cannabis plant and its synthetic derivatives produce several structural isomers — molecules with the same molecular formula arranged differently — each with distinct pharmacological profiles.
Delta-9-THC is the primary naturally occurring psychoactive cannabinoid and the pharmacological reference compound for potency, effects and drug testing.
Delta-8-THC is a structural isomer where the double bond is on the 8th carbon position rather than the 9th. It occurs naturally at under 1% in cannabis but is predominantly manufactured through acid-catalysed isomerisation of CBD. Delta-8 binds CB1 receptors at approximately 50–66% of delta-9’s affinity, producing milder psychoactive effects. Users consistently report less anxiety and paranoia compared to delta-9. Its legal status under the 2018 US Farm Bill was ambiguous; regulators increasingly treat it as a controlled substance analogue.
Delta-10-THC is another positional isomer found in trace amounts in cannabis. It reportedly produces energising, sativa-like effects. Relatively little clinical receptor pharmacology data has been published compared to delta-8.
THCV (tetrahydrocannabivarin) has a 3-carbon propyl side chain instead of the 5-carbon pentyl chain of delta-9. This creates paradoxical pharmacology: low doses act as CB1 antagonists (suppressing appetite); high doses act as partial CB1 agonists with mild psychoactivity. THCV also activates CB2 receptors and has demonstrated anti-diabetic properties in rodent studies. Found in higher concentrations in African sativa landraces.
THCP (tetrahydrocannabiphorol) was identified by Italian researchers in 2019. It has a 7-carbon alkyl chain, compared to delta-9’s 5-carbon chain. Binding studies showed 33× greater CB1 affinity than delta-9-THC, with mouse studies confirming pharmacological activity at 10× lower doses. Natural concentration in cannabis is extremely low (micrograms per kilogram), but synthetic THCP products have emerged on the market.
THC’s medical applications span several decades of clinical investigation. Dronabinol (synthetic delta-9-THC) and nabilone (synthetic THC analogue) received FDA approval in the United States for chemotherapy-induced nausea and vomiting (CINV) and AIDS-related anorexia — the first cannabis-derived pharmaceutical approvals in the West.
In chronic pain management, a 2018 meta-analysis in JAMA found medical cannabis significantly reduced chronic non-cancer pain compared to standard care in approximately 30% of randomised controlled trials. Neuropathic pain — poorly responsive to conventional analgesics — showed the most consistent benefit from THC-containing preparations. Multiple sclerosis spasticity has strong clinical evidence supporting THC use; Nabiximols (Sativex, a 1:1 THC:CBD oromucosal spray) is approved in over 30 countries for this indication.
PTSD research has gained momentum following observational evidence from veteran populations. Small randomised trials show THC reduces frequency and severity of trauma-related nightmares, improves sleep quality and reduces overall PTSD symptom scores. The mechanism involves THC facilitating fear extinction through CB1 receptor activation in the amygdala, which appears to accelerate the processing and contextualisation of traumatic memories.
Appetite stimulation has clinical application in cancer cachexia and HIV/AIDS wasting syndrome. THC activates CB1 receptors in hypothalamic appetite-regulating centres, stimulating orexigenic pathways and enhancing olfactory sensitivity, making food more appealing. Clinical trials with dronabinol in AIDS patients demonstrated significant appetite increases and weight stabilisation versus placebo.
Drug testing for cannabis targets THC-COOH (11-nor-9-carboxy-THC), the primary urinary metabolite, rather than THC itself. THC-COOH is inactive but accumulates in fatty tissue and is excreted slowly over days to weeks. Standard urine immunoassay cut-off is 50 ng/mL, confirmed at 15 ng/mL by GC-MS or LC-MS/MS.
| Test Type | Target Compound | Single Use Window | Daily Use Window |
|---|---|---|---|
| Urine (IA) | THC-COOH | 3–7 days | 30–90 days |
| Blood (GC-MS) | Delta-9-THC + metabolites | 6–24 hours | Up to 14 days |
| Saliva | Delta-9-THC | 24–48 hours | Up to 72 hours |
| Hair follicle | THC-COOH (embedded) | Up to 90 days | Up to 90 days |
THC does not act in isolation within the cannabis plant or in the body. Its effects are modulated by interactions with other cannabinoids and terpenes — the entourage effect, first described by Mechoulam and Ben-Shabat in 1998 and expanded by Ethan Russo in 2011. CBD is the most studied modulator: as a negative allosteric modulator of CB1 receptors, CBD changes the receptor’s conformation to reduce the maximum response THC can achieve, providing a biochemical basis for the "balanced" experience of higher-CBD strains. CBD also inhibits the CYP2C9 enzyme responsible for THC metabolism, potentially extending THC’s duration while reducing peak plasma concentrations.
Terpenes contribute to THC pharmacology beyond mere aroma. Myrcene potentiates sedative effects through GABA-A receptor modulation. Pinene may reduce THC-induced memory impairment by inhibiting acetylcholinesterase. Limonene interacts with serotonin receptors independent of cannabinoid mechanisms. Caryophyllene activates CB2 receptors directly without CB1 involvement, adding anti-inflammatory pathways that synergise with THC’s analgesic effects. Understanding these interactions is fundamental to understanding why whole-plant cannabis products often produce qualitatively richer effects than isolated THC at the same dose.
THC is the compound most national drug laws target when scheduling cannabis. Under the 1971 UN Convention on Psychotropic Substances, THC is Schedule I. In the United States, delta-9-THC in cannabis remains Schedule I federally, while individual states have enacted varying medical and recreational legalisation frameworks. In Europe, most countries define "hemp" by THC content below 0.3% dry weight; products above this threshold are classified as controlled cannabis. Germany’s Cannabis Act (CanG) enacted in 2024 legalised recreational possession and limited home cultivation. Synthetic THC pharmaceuticals (dronabinol, nabilone) typically hold Schedule II or prescription-only status in many jurisdictions, reflecting their recognised medical utility. Novel isomers — THCP, delta-8, delta-10 — occupy regulatory grey areas that enforcement agencies are progressively closing through analogue drug legislation.
Understanding how cannabis produces THC illuminates why different growing conditions, genetics and plant stress affect final cannabinoid content. THC biosynthesis begins with geranyl pyrophosphate (GPP), combined with olivetolic acid by the enzyme GOT to produce cannabigerolic acid (CBGA). In plants with dominant THCA synthase gene expression, CBGA is converted by THCA synthase to THCA through an oxidative cyclisation reaction forming the characteristic three-ring cannabinoid skeleton. Plants with CBDA synthase dominance instead produce CBD-dominant chemotypes. The relative expression of these competing synthase enzymes — determined by genetics — is the primary driver of a plant's cannabinoid ratio.
Trichomes are the biosynthetic factories for THC. These glandular structures, primarily capitate-stalked trichomes on female flower bracts, contain the enzymatic machinery for cannabinoid biosynthesis. THCA concentrations in mature trichome heads can exceed 30% of the trichome mass itself. Trichome density and morphology are therefore primary determinants of a cultivar's potency ceiling, and selective breeding has progressively intensified trichome production over generations. Environmental stress — moderate drought, temperature fluctuation and UV-B light exposure — triggers increased trichome density and THCA production as a putative plant defence mechanism, explaining why high-altitude outdoor grows with intense UV exposure can produce exceptionally potent flower.
THC exerts its effects by molecular mimicry of the body's endocannabinoid system (ECS), discovered in the early 1990s as a direct consequence of THC research. The ECS comprises CB1 and CB2 receptors, endogenous ligands (endocannabinoids), and their synthesising/degrading enzymes. The two primary endocannabinoids — anandamide (AEA) and 2-arachidonoylglycerol (2-AG) — are synthesised on demand from membrane phospholipid precursors and rapidly degraded by FAAH and MAGL enzymes respectively. They function as retrograde neuromodulators: released post-synaptically to regulate upstream neurotransmitter release.
THC mimics endocannabinoids structurally but with a critical pharmacokinetic difference: THC resists rapid enzymatic degradation by FAAH and MAGL, giving it a much longer receptor residence time than endogenous ligands. This extended CB1 occupation is responsible for both the prolonged duration of THC effects and the tolerance development that occurs with regular use as receptors downregulate. The ECS regulates pain modulation, immune function, memory formation, appetite, stress response, reproductive function and sleep-wake cycling — explaining the broad therapeutic potential of THC across multiple conditions and the qualitatively distinct effects felt throughout the body rather than in a single system.
THC stands for tetrahydrocannabinol — specifically delta-9-tetrahydrocannabinol. It is the primary psychoactive cannabinoid in cannabis, binding to CB1 receptors in the brain to produce the psychoactive effects associated with cannabis use.
THCA is the non-intoxicating acidic precursor to THC found in raw, fresh cannabis. It must be decarboxylated by heat (approximately 104–115°C) to convert to active delta-9-THC. Raw cannabis does not produce psychoactive effects until heated.
No. Delta-8-THC is a structural isomer of delta-9-THC with the double bond on the 8th carbon. It binds CB1 receptors at approximately half the potency, producing milder effects with reportedly less anxiety. Most commercial delta-8 is synthesised from CBD rather than extracted from cannabis.
Detection windows: urine 3–7 days (single use) to 90 days (heavy daily); blood 6 hours to 14 days; saliva 24–72 hours; hair up to 90 days. Urine tests target the inactive metabolite THC-COOH, not psychoactive THC itself.